国际肿瘤学杂志

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (7): 495-499.doi: 10.3760/cma.j.issn.1673422X.2014.07.005

• 综述 • 上一篇    下一篇

嵌合抗原受体修饰T细胞在恶性肿瘤中的研究进展


张少华,毕经旺   

  1. 250031 济南军区总医院肿瘤科（张少华、毕经旺）；辽宁医学院研究生院（张少华）
  • 出版日期:2014-08-04 发布日期:2014-08-04
  • 通讯作者: 毕经旺， Email：jingwangbi@live.cn E-mail:jingwangbi@live.cn

The progression of chimeric antigen receptor modified T cells in malignant tumor

 ZHANG  Shao-Hua, BI  Jing-Wang   

  1. *Departments of Oncology，The General Hospital of Jinan Military Command，Jinan 250031,China
  • Online:2014-08-04 Published:2014-08-04
  • Contact: Bi Jingwang E-mail:jingwangbi@live.cn

PDF

2082

被引次数

1

摘要： 近年来在肿瘤免疫治疗领域，嵌合抗原受体（CAR)修饰T细胞在基础研究和临床试验中取得了巨大进展。CAR由特异性单克隆抗体的可变区和CD3ζ结构域组成。CAR修饰T细胞的胞外区直接识别肿瘤相关抗原（TAA)。T细胞和靶抗原结合后可直接介导细胞毒性，并释放一些细胞因子如穿孔素、颗粒酶、干扰素γ（IFNγ）和肿瘤坏死因子α（TNFα），最终导致肿瘤细胞的坏死。尽管CART细胞具有显著的抗肿瘤效应，一些基础研究和临床实验中观察到的安全性问题值得关注。

关键词: 肿瘤, 免疫疗法, 嵌合抗原受体

Abstract: Recent years have witnessed much progress in both basic research and clinical trials regarding cancer immunotherapy with chimeric antigen receptor (CAR)engineered T cells. CAR combine the variable regions of a specific monoclonal antibody (scFv) with the CD3ζ endodomain.The extracellular domain of CARengineered T cells directly dock to the tumorassociated antigen (TAA). When T cells bind to target antigens，they mediated redirected cytotoxicity and secrete a series of cytokines such as Perforin, Granzyme, Interferonγ （IFNγ）and Tumor necrosis factorα （TNFα）,  which would eventually lead to the necrosis of tumor cells. Although the antitumor response of the CARengineered T cells is considered as successful and surprising, it should be noted that some safety issues have been observed in other several basic researches and clinical trials. This overview focuses upon the utility and safety of the CARengineered T cells.

Key words: Neoplasms, Immunotherapy, Chimeric antigen receptor